28 Oct 2026 Research & Development Spotlight Series – Episode 18 – AVA6000 at ESMO 2026 Investors | R&D Spotlights Series
27 Oct 2026 Research & Development Spotlight Series – Episode 17 – AVA6103 at ESMO 2026 Investors | R&D Spotlights Series
26 Oct 2026 Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers Investors | Therapeutics
23 Oct 2026 Avacta Highlights pre|CISION Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103) Investors | Therapeutics
14 Oct 2026 Avacta to Present Progression Free Survival Data on Faridoxorubicin (AVA6000) and the FOCUS-01 (AVA6103) Trial Design at the ESMO 2026 Congress Investors | Therapeutics